Nerve block may halt prostate cancer progression
NCT ID NCT06703437
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a long-acting nerve block, given during a standard prostate biopsy, can slow the growth of high-risk prostate cancer. The block uses lidocaine and dehydrated alcohol to temporarily stop signals from nerves that may help cancer spread. Only 12 men with high-risk features will take part, and the main goal is to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dehydrated alcohol (ethanol) and lidocaine
What this could lead to
If it works, this could point toward a way to slow prostate cancer growth by blocking nerve signals.
What could go wrong
This is a very early phase 1 safety trial with only 12 people. It is designed to find a safe dose, not to prove the treatment works. Side effects from the nerve block are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States